Atirmociclib - Pfizer
Alternative Names: PF-07220060Latest Information Update: 31 Jan 2025
At a glance
- Originator Pfizer
- Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Breast cancer; Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 07 Jan 2025 Pfizer plans phase-III FourLight-3 trial for HER2-negative bBreast cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in USA (PO, Tablet) in February 2025 (NCT06760637),
- 06 Jan 2025 Phase-III clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in Japan and USA (PO) (EudraCT2024-512925-95-00) (NCT06760637)
- 24 Dec 2024 Chemical structure information added.